ReviewMyManuscript logo
Review My ManuscriptAI-assisted pre-review
Illustrative AI review — based on a real open-access article (Yusong Luan et al., Frontiers in Oncology, 2022; DOI: 10.3389/fonc.2022.850937; License: CC-BY 4.0). Not a real journal decision.
Sample / illustrative report only — fictional neuro-oncology manuscript for UI demo. Not a real patient case, not a journal decision. Upload your own manuscript to receive a real review.
ANALYSIS REPORTFictional sample05.07.2026

Prognostic Factors in Stage IV Colorectal Cancer Patients With Resection of Liver and/or Pulmonary Metastases: A Population-Based Cohort Study

Font size:
View:

This is a concise overview. Switch to Full evaluation (Detailed) above for the complete report.

Key Points

  • 1SEER-based cohort of 3,003 stage IV colorectal cancer patients identifying prognostic factors after metastatectomy; STROBE-relevant gaps in confounding adjustment, competing-risk analysis, and subgroup multiplicity weaken the causal interpretation of key findings.

Major Issues

Methods: SEER lacks data on systemic chemotherapy and targeted agents (e.g., FOLFOX, FOLFIRI, bevacizumab, cetuximab); omission of treatment covariates introduces substantial unmeasured confounding, as treatment selection drives OS independently of surgical resection.
Statistics: Competing-risk analysis for non–cancer-specific death is absent; in older stage IV CRC patients, non-cancer death is non-trivial and the standard Kaplan–Meier estimator over-estimates cancer mortality risk when competing events are common.
Statistics: Proportional hazards assumption is not tested; given the long follow-up (up to 8 years), time-varying effects of stage and site are plausible and should be checked with Schoenfeld residuals or log–log plots.
Results / Discussion: At least eight subgroup comparisons are reported without multiple-testing correction, inflating familywise type-I error; statistically significant subgroup differences should be interpreted as hypothesis-generating only.
Discussion: Causal interpretation language ('liver metastases resection leads to better survival') is applied to an observational SEER dataset without accounting for selection bias, immortal-time effects, or indication bias inherent in who receives surgical resection.

Priority Action Plan

HIGH IMPACT

Problem

Add competing-risk analysis (Fine–Gray) for cancer-specific survival as a co-primary endpoint to address non-cancer mortality bias.

Why it matters

Kaplan–Meier OS in older oncology cohorts systematically overestimates cancer risk.

Suggested fix

Add competing-risk analysis (Fine–Gray) for cancer-specific survival as a co-primary endpoint to address non-cancer mortality bias.

HIGH IMPACT

Problem

Perform a sensitivity analysis adjusting for chemotherapy receipt proxy or restricting to post-2012 enrolees to reduce unmeasured treatment confounding.

Why it matters

Treatment heterogeneity is the primary threat to validity; without adjustment, HRs for surgical factors are uninterpretable.

Suggested fix

Perform a sensitivity analysis adjusting for chemotherapy receipt proxy or restricting to post-2012 enrolees to reduce unmeasured treatment confounding.

MEDIUM IMPACT

Problem

Apply FDR correction to subgroup analyses and reframe significant subgroup findings as hypothesis-generating.

Why it matters

Multiple uncorrected comparisons inflate type-I error; current interpretation overstates certainty of laterality and site effects.

Suggested fix

Apply FDR correction to subgroup analyses and reframe significant subgroup findings as hypothesis-generating.

Quick win: Prioritise competing-risk analysis and treatment confounding adjustments before resubmitting. Subgroup correction and causal language softening are secondary but important for peer scrutiny at high-impact oncology journals.

Upload your manuscript
Open interactive sampleHow journal fit worksSample reports hubDesk-reject guides
Illustrative AI review sample — oncology | Review My Manuscript